EUVIMEDEUVIMED entdecken
Crossref

Imidazolyl Lipids Enhanced LNP Endosomal Escape for Ferroptosis RNAi Treatment of Cancer

Yuanyuan Liu, Fengyang He, Longming Chen, Yahan Zhang, Han Zhang, Junhai Xiao, Qingbin Meng iD

Small · 2024

DOI: 10.1002/smll.202402362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, 2024. Verfasst von Yuanyuan Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of National Security Specially Needed Medicines, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing, 10…. Hauptthemen laut MEDLINE: Ferroptosis, RNA, Small Interfering, Nanoparticles, Lipids. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatments for cancer that incorporate small interfering RNA (siRNA) to target iron‐dependent ferroptosis are thought to be highly promising. However, creating a reliable and clinically feasible siRNA delivery system continues to be a major obstacle in the field of cancer treatment. Here, three imidazole‐based ionizable lipid nanoparticles (LNPs) with pH‐sensitive effects are rationally designed and synthesized for siRNA delivery. LNPs formulated with the top‐performing lipid (O12‐D3‐I3) encapsulating FVII siRNA (FVII@O‐LNP) elicited greater gene silencing than those with the benchmark Onpattro lipid DLin‐MC3‐DMA (MC3) due to its stronger endosomal escape. Moreover, Fc‐siRNA@O‐LNPs encapsulated with ferrocene (Fc) and SLC7A11/Nrf2‐targeted siRNA is formulated. The outcomes demonstrate optimal safety profiles and a significant anti‐tumor effect by inducing long‐lasting and efficient ferroptosis through a synergistic action in vivo. In summary, this work shows that imidazolyl lipid‐prepared LNPs are efficient delivery vehicles for cancer therapy and ferroptosis‐targeting siRNA administration, both of which have extensive clinical application potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisRNA, Small InterferingNanoparticlesLipidsEndosomesImidazolesHumansAnimalsCell Line, TumorNeoplasmsRNA InterferenceMice

Stichwörter der Autor:innen

LNPs encapsulated siRNA deliverycellular uptakeferroptosisionizable lipidstumor synergistic therapy

Substanzen

RNA, Small InterferingLipidsImidazolesimidazole

Autor:innen und Institutionen

  • State Key Laboratory of National Security Specially Needed Medicines, Beijing Institute of Pharmacology and Toxicology, 27 Tai-Ping Road, Beijing, 100850, China.

ORCID-Profile: Qingbin Meng

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, Y., He, F., Chen, L., Zhang, Y., Zhang, H., Xiao, J., & Meng, Q. (2024). Imidazolyl Lipids Enhanced LNP Endosomal Escape for Ferroptosis RNAi Treatment of Cancer. Small. https://doi.org/10.1002/smll.202402362

Vancouver

Liu Y, He F, Chen L, Zhang Y, Zhang H, Xiao J, et al. Imidazolyl Lipids Enhanced LNP Endosomal Escape for Ferroptosis RNAi Treatment of Cancer. Small. 2024. doi:10.1002/smll.202402362

BibTeX
@article{Liu2024,
  author = {Liu, Yuanyuan and He, Fengyang and Chen, Longming and Zhang, Yahan and Zhang, Han and Xiao, Junhai and Meng, Qingbin},
  title = {Imidazolyl Lipids Enhanced LNP Endosomal Escape for Ferroptosis RNAi Treatment of Cancer},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202402362}
}
Kostenlos starten →